Dr Picozzi talks to ecancer about data from the phase 3 PANOVA-3 trial he presented at ASCO 2025.

The results demonstrated that adding tumor treating fields (TTFields) therapy to gemcitabine and nab-paclitaxel improved overall survival and pain-free survival in patients with locally advanced pancreatic adenocarcinoma (LA-PAC), without increasing systemic toxicity.

He notes that these results mark the first phase 3 evidence of a survival benefit in LA-PAC, positioning TTFields as a promising new treatment option, supported by favourable safety and enhanced distant progression-free survival outcomes.